Prostate News and Research

RSS

ICU-related mortality may explain variations in cancer outcomes

A Scottish population-based study has characterised the incidence of critical illness resulting in admission to an intensive care unit during the first 2 years after a cancer diagnosis.

9 Sep 2015

Three drug-like compounds may offer better odds of survival to patients with prostate cancer, find SMU researchers

Researchers at Southern Methodist University, Dallas, have discovered three new drug-like compounds that could ultimately offer better odds of survival to prostate cancer patients.

9 Sep 2015

NxThera obtains FDA clearance for Rezūm System to treat BPH

NxThera, Inc., a medical device company pioneering the application of its Convective Water Vapor Energy (WAVE) platform technology to treat endourological conditions, is pleased to announce it has received FDA 510(k) clearance of the company's Rezūm System to treat BPH.

3 Sep 2015

Men with relatively unaggressive prostate tumors unlikely to develop metastatic prostate cancer

Men with relatively unaggressive prostate tumors and whose disease is carefully monitored by urologists are unlikely to develop metastatic prostate cancer or die of their cancers, according to results of a study by researchers at the Brady Urological Institute at Johns Hopkins, who analyzed survival statistics up to 15 years.

1 Sep 2015

Robotic surgeon offers free consultation for patients diagnosed with prostate cancer

September marks the beginning of Prostate Cancer Awareness Month. World renowned robotic prostate cancer surgeon, Dr. David Samadi, is offering a free phone consultation for patients newly diagnosed with Prostate Cancer.

1 Sep 2015

Northwestern University receives $11.7 million NCI grant to use nanotechnology for cancer treatments

Northwestern University, a leader in cancer nanotechnology research, has received a five-year, $11.7 million grant from the National Cancer Institute to use nanotechnology to develop next-generation cancer treatments.

1 Sep 2015

Moffitt researchers hope to improve pancreatic cancer survival rates by developing blood test to identify IPMNs

Pancreatic cancer is the fourth most common cause of cancer-related death in the United States and has a 5-year survival rate of only 6 percent, which is the lowest rate of all types of cancer according to the American Cancer Society.

29 Aug 2015

Robotically-steered flexible needles may improve diagnostic and therapeutic procedures

Robotically steering flexible needles can reach their intended target in tissue with sub-millimetre level accuracy. This has been demonstrated by the doctoral research of Momen Abayazid, who is affiliated with the research institute MIRA of the University of Twente. An major advantage of steering flexible needles is that one can avoid obstacles or sensitive tissues and can re-orient the path of the needle in real time as you insert the needle.

28 Aug 2015

Adaptive immune system plays active role in guiding development of mammary glands

In experiments with mouse tissue, UC San Francisco researchers have discovered that the adaptive immune system, generally associated with fighting bacterial and viral infections, plays an active role in guiding the normal development of mammary glands, the only organs--in female humans as well as mice--that develop predominately after birth, beginning at puberty.

28 Aug 2015

Global urinary catheters market to expand at 4.1% CAGR between 2015 and 2021

According to a new market report published by Persistence Market Research titled "Global Market Study on Urinary Catheters: Intermittent Catheters Segment to Witness Highest Growth by 2021", the urinary catheters market is expected to be valued at US$1,377.5 Mn by the end of 2015. It is anticipated to expand at a CAGR of4.1% from 2015 to 2021, to reach US$1,755.0 Mn by 2021.

From B. Braun Melsungen AG 27 Aug 2015

New NCCN Guidelines for Patients and NCCN Quick Guide for Kidney Cancer published

Kidney Cancer is among the 10 most diagnosed cancers in both men and women in the United States, and it is estimated that more than 60,000 new cases of kidney cancer will be diagnosed in 2015.

27 Aug 2015

ASTRO awards $675,000 to seven physician-researchers to advance radiation oncology research

The American Society for Radiation Oncology has selected seven leading physician-researchers to receive a total of $675,000 in awards and grants to advance radiation oncology research. Together, the seven funding grants, including ASTRO Junior Faculty Career Research Training Award, the ASTRO Residents/Fellows in Radiation Oncology Research Seed Award and the ASTRO/Radiation Oncology Institute Comparative Effectiveness Research Award, will support studies in radiation and cancer biology, radiation physics, translational research, outcomes/health services research and comparative effectiveness research within radiation oncology.

27 Aug 2015

New research finds five different types of prostate cancer

New research has revealed that five different types of prostate cancer exist. How will this discovery change the outlook of prostate cancer screening? World renowned robotic prostate cancer surgeon, Dr. David Samadi, evaluates.

25 Aug 2015

Electronic triggers can help identify, reduce follow-up delays in evaluation for cancer diagnosis

Electronic triggers designed to search for key data, developed by researchers at Baylor College of Medicine and Michael E. DeBakey Veterans Affairs Medical Center, were able to identify and reduce follow-up delays for patients being evaluated for a diagnosis of colon or prostate cancer.

25 Aug 2015

Esperance, MD Anderson form strategic alliance to accelerate development of anti-cancer candidate EP-100

Esperance Pharmaceuticals Inc. today announced that it has entered into a strategic alliance agreement with MD Anderson Cancer Center to accelerate the clinical development of its lead anti-cancer candidate EP-100 for the treatment of ovarian cancer and to collaborate on preclinical studies of EP-100 as a treatment for breast cancer.

24 Aug 2015

Berg and University of Miami extend partnership to battle cardiac dysfunction, heart failure

Berg, a Boston-based biopharmaceutical company, and the University of Miami Leonard M. Miller School of Medicine are extending its collaboration to battle cardiac dysfunction and heart failure. According to the American Heart Association, cardiovascular disease is the leading global cause of death, accounting for 17.3 million deaths per year, a number that is expected to grow to more than 23.6 million by 2030.

23 Aug 2015

MTG Biotherapeutics' MTG-201 granted FDA Orphan Drug Designation for malignant mesothelioma treatment

MTG Biotherapeutics, an immuno-oncology company developing novel therapeutics for the treatment of cancer, today announced that the US Food and Drug Administration has granted Orphan Drug Designation for MTG-201, an advanced biologic therapy targeting Dickkopf-3 gene defects in various cancers, for the treatment of malignant mesothelioma.

23 Aug 2015

PSMA PET imaging more precise than MR imaging for detection of high-grade prostate cancer lesions

A molecular imaging biomarker is able to detect fast-growing primary prostate cancer and distinguish it from benign prostate lesions, addressing an unmet clinical need. The new research, published in the July 2015 issue of The Journal of Nuclear Medicine, is significant for patients with suspected prostate cancer that has not been confirmed by standard biopsy.

21 Aug 2015

Newly developed oxidation process uses ozone to degrade contaminants in water

At the Center for Research and Assistance in Technology and Design of the State of Jalisco (CIATEJ) at the east of Mexico, an oxidation process was developed that uses ozone to degrade contaminants in water that alter the synthesis, transport, action or elimination of natural hormones, responsible for maintain self-regulation of metabolic and reproductive processes in living beings.

18 Aug 2015

Mylan sued in connection with ANDA filing for generic version of Zytiga

Mylan N.V. today confirmed that the company has been sued by BTG International Ltd., Janssen Biotech, Inc., Janssen Oncology, Inc., and Janssen Research & Development, LLC in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration for Abiraterone Acetate Tablets, 250 mg.

18 Aug 2015

Prostate News and Research

ICU-related mortality may explain variations in cancer outcomes

Three drug-like compounds may offer better odds of survival to patients with prostate cancer, find SMU researchers

NxThera obtains FDA clearance for Rezūm System to treat BPH

Men with relatively unaggressive prostate tumors unlikely to develop metastatic prostate cancer

Robotic surgeon offers free consultation for patients diagnosed with prostate cancer

Northwestern University receives $11.7 million NCI grant to use nanotechnology for cancer treatments

Moffitt researchers hope to improve pancreatic cancer survival rates by developing blood test to identify IPMNs

Robotically-steered flexible needles may improve diagnostic and therapeutic procedures

Adaptive immune system plays active role in guiding development of mammary glands

Global urinary catheters market to expand at 4.1% CAGR between 2015 and 2021

New NCCN Guidelines for Patients and NCCN Quick Guide for Kidney Cancer published

ASTRO awards $675,000 to seven physician-researchers to advance radiation oncology research

New research finds five different types of prostate cancer

Electronic triggers can help identify, reduce follow-up delays in evaluation for cancer diagnosis

Esperance, MD Anderson form strategic alliance to accelerate development of anti-cancer candidate EP-100

Berg and University of Miami extend partnership to battle cardiac dysfunction, heart failure

MTG Biotherapeutics' MTG-201 granted FDA Orphan Drug Designation for malignant mesothelioma treatment

PSMA PET imaging more precise than MR imaging for detection of high-grade prostate cancer lesions

Newly developed oxidation process uses ozone to degrade contaminants in water

Mylan sued in connection with ANDA filing for generic version of Zytiga

What to know about prostate cancer eBook

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News